Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis

BACKGROUND: Methotrexate (MTX) is a disease modifying antirheumatic drug (DMARD) used as a first line agent for treating rheumatoid arthritis (RA). Pharmacologically, it is classified as an antimetabolite due to its antagonistic effect on folic acid metabolism. Many patients treated with MTX experie...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cochrane Database Syst Rev
Glavni autori: Shea, Beverley, Swinden, Michael V, Tanjong Ghogomu, Elizabeth, Ortiz, Zulma, Katchamart, Wanruchada, Rader, Tamara, Bombardier, Claire, Wells, George A, Tugwell, Peter
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Ltd 2013
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7046011/
https://ncbi.nlm.nih.gov/pubmed/23728635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD000951.pub2
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items